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Human B-cell lymphomas, the fourth most common hematologic malignancy, are currently the subject of extensive research.
The limited accessibility of biopsies, the heterogeneity among patients, and the subtypes of lymphomas have necessitated the
development of animal models to decipher immune escape mechanisms and design new therapies. Here, we summarize the cell
lines and murine models used to study lymphomagenesis, the lymphoma microenvironment, and the eﬃcacy of new therapies.
These data allow us to understand the role of the immune system in the ﬁght against tumors. Exploring the advantages and
limitations of immunocompetent versus immunodeﬁcient models improves our understanding of the molecular and cellular
mechanisms of tumor genesis and development as well as the fundamental processes governing the interaction of tumors and
their host tissues. We posit that these basic preclinical investigations will open up new and promising approaches to designing
better therapies.
1.Introduction
Lymphomas are highly heterogeneous diseases, varying by
boththe type of malignant cell and the tumor location. They
most frequently originate from B cells, and the two main
groupsofB-cell lymphomas, B-cellnon-Hodgkin lymphom-
as (NHL) and Hodgkin lymphomas, account, respectively,
for about 80% and 15% of all lymphomas. Of the NHL, half
are diﬀuselarge B-celllymphomas, followed in prevalenceby
follicular lymphomas, marginal zone lymphomas, Burkitt’s
lymphomas, and mediastinal lymphomas. This heterogene-
ity makes it diﬃcult to collect human samples in suﬃcient
quantities for statistical analyses. Moreover, these samples
are not easy to classify in the absence of clear discriminative
parameters. In addition, some tumors, such as primary
central nervous system (CNS) lymphomas, are located deep
within delicate tissues, which complicates the collection of
biopsy samples and complete tumor analysis [1]. Studying
these tumors is thus quite challenging. Animal models are
very useful, because they let us work on very homogeneous
materials. They are also essential for preclinical studies and
allow us to perform kinetic analyses together with detailed
investigation of the tumors’ characteristics and microen-
vironments. Here, we will review the spontaneous and in-
duced B-cell lymphoma models that can occur in transgenic
mice, or by various types of transfer of tumor cells into2 Advances in Hematology
wild-type mice (Figure 1). We will summarize the known
categories of B-cell lymphoma mouse models and discuss
their experimental and translational values. Finally, we will
examine how the tumors regulatetheir microenvironment in
diﬀerent tissues and how this knowledge could be translated
into practical applications for tumor therapies.
2.ModelsforStudyingLymphomagenesis
Oneofthekeyquestionsabouttumordevelopmentconcerns
the origin and the mechanisms responsible for malignant
phenotypes. Various spontaneous tumor models have been
developed to study how B-cell lymphomas arise and mature
in diﬀerent tumor environments. Observations and exper-
iments with human tissue samples have provided some
indications about the possible genetic events that might be
responsible for uncontrolled B-cell proliferation. Recent ad-
vances in genetic engineering have made it possible to de-
velop transgenic mouse models recapitulating major known
modiﬁcations of the genome and to infect mice with viruses
that can induce B-cell lymphomas.
The myc oncogene is the gene most frequently studied:
its translocation behind an enhancer or promoter region
speciﬁc for B lymphocytes can give rise to B-cell lymphomas
(Table 1). The involvement of such a translocation in lym-
phomagenesis is studied in the most used mouse model, Eμ-
Myc. Inthis transgenic experimental tumormodel, when the
myc gene is inserted into the IgH locus, B-cell lymphomas
develop at a 100% incidence rate. Nonetheless, disease onset
is, as in humans, highly variable (from day 32 to day 600), as
is the phenotype of the tumors in diﬀerent mice. More pre-
cisely, Mori and colleagues [14] have described two principal
tumor phenotypes: the ﬁrst type arises during an early time
window and is composed mainly of immature B cells, thus
resembling Burkitt’s lymphoma. The second type develops
very late (after day 400) and is composed of mature B cells;
it is similar to diﬀuse large B-cell lymphomas [14]. Interest-
ingly, if the myc gene is placed under the enhancer region of
the Ig light chain genes, it results in a disease very similar
to Burkitt’s lymphoma in humans [7]( Table 1). Sheppard
and colleagues [4] generated another transgenic mouse with
the translocation of the N-myc gene under the IgH enhancer
and with only a subtle modiﬁcation of the endogenous myc
expression level.Thisresultedin anindolentdiseaseand only
25% incidence after 9 to 12 months. After infection with
the murine Moloney leukemia virus, however, both the inci-
dence and speed of tumor developmentwere far greater. Fol-
lowing this idea,othersdevelopeda model that usesthe Brd2
gene and can induce B-cell lymphoma in some mice after
translocation but is not suﬃcient to obtain a high incidence.
Modiﬁcation of these mice by infection with a retrovirus
expressing the ras oncogene also aggravated and accelerated
lymphomagenesis [10](Table 1).These resultspointoutthat
translocation ofthe oncogeneby itselfis not suﬃcientto cre-
ate a malignant phenotype. The added value of these trans-
genic models is that tumors develop on a syngeneic back-
ground that makes it possible to analyze the tumor microen-
vironment and its inﬂuence on tumor growth. For example,
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Figure 1: Schematic representation of the major subtypes of B-
cell lymphoma murine models. Murine models can be either
spontaneous and develop in genetically engineered mice or can be
induced by implantation of a tumor cell line. In this case, it is
possibleto injectcells inlymphnodes (nodallocation)oroutsideof
them (extranodal location). Immune sanctuaries such as the brain
or the eyes provide informationabout that particular situation,but
many other sites can be envisaged.
by studying the inﬂuence of Bcl2 overexpression in the he-
matologic compartment in generating a follicular B-cell
lymphoma,Egleandcollaborators[8]wereabletodetermine
thatCD4+ Tcellswerecrucialintheproliferationofgerminal
center B cells and therefore in lymphomagenesis.
To understand the mechanisms linked to lymphomagen-
esis in more detail, researchers have introduced more strate-
gies to transfer variously modiﬁed tumor cells into im-
munodeﬁcient or immunocompromised hosts (models list-
ed in Tables 2 and 3). These approaches introduce the
potential bias of tumor injection to speciﬁc tissue sites and
are unable to follow the progressive induction and develop-
ment of tumors from a few malignant cells. Despite these
weaknesses, tumor injection models are very useful because
they let us study the impact of diﬀerent mutations on tumor
aggressiveness (models listed in Table 2). For example, the
potential role of pax5 in lymphomagenesis was studied with
cell lines deﬁcient for this gene [17]. Using the same idea, Yu
and collaborators [18] developed a strategy to determine the
inﬂuenceofdiﬀerentgenesinenhancingthetumor-inducing
potential of the myc gene translocation (Table 3). By mixing
bone marrow from p53 null mice with a packaging cell line
producing the myc-encoding retrovirus, they demonstrated
that p53 inactivation together with myc overexpression was
suﬃcient to induce B-cell lymphomas. These models could
easily andrapidlybeadaptedtohelpdeﬁnetheeﬀectofother
genes and gene interactions on lymphomagenesis without
the need to develop transgenic mice.
T h ed i v e r s i t yo ft h ea n i m a lm o d e l sl i s t e di nT a b l e s1–3
makes it very challenging to study the inﬂuence of diﬀerent
characteristics on the development of speciﬁc types of tu-
mors in experimental animals and to draw signiﬁcant con-
clusions about human B-cell lymphoma development.Some
models are heterogeneous [14] or can only be classiﬁed
depending on the diﬀerentiation stage of the tumor cells
used [47] ,w h i l es o m et r a n s g e n i cm i c ea r ec l e a r l ya s s o c i a t e d
with speciﬁc B-cell lymphoma phenotypes. Some models
are nonetheless very useful for studying human disease. For
example, because NFS.V mice develop tumors that are very
similar to marginal zone lymphomas [5], they provided a
basis for deﬁning its stages of progression (Table 1). Another
highly relevant tumormodel isthe blastoidvariant ofmantleAdvances in Hematology 3
Table 1: Spontaneous models of B-cell lymphoma. B-NHL: non-Hodgkin B-cell lymphoma; CLL: chronic lymphocytic leukemia; DLBCL:
diﬀuse large B-cell lymphoma;DTG: double transgenic mice; n.d.: not determined.
Name Lymphoma subtype/orgin Strain (haplotype) Major
reference
B10 H-2a H-4bp/Wts CLL C57Bl/10 (H-2b)[ 2]
SL/KH Pre-B lymphoma SL/KH (H-211)[ 3]
Eμ-N-myc Indolent B-NHL C57Bl/6 x DBA/2 (H-2b/d)[ 4]
NFS.V+ Marginal zone lymphoma NFS.V+ (H-2sq4)[ 5]
NMRI/RFB-MuLV n.d. NMRI (H-2q)[ 6]
B6-l-MYC Burkitt-like lymphoma C57Bl/6 (H-2b)[ 7]
VavP-Bcl2 Follicular lymphoma C57Bl/6 (H-2b)[ 8]
Lig4/p53 KO Pro/Pre-B lymphoma C57Bl/6 × sv129 [9]
Eμ-BRD2 DLBCL FVB (H-2q)[ 10]
Bcl6 Knock in Germinal center, DLBCL C57Bl/6 × sv129 [11]
Bcl6/Myc transgenic Post germinal center, DLBCL C57Bl/6 × sv129 [11]
IL-14aTGxc-Myc TG (DTG) Blastoid variant of mantle-cell lymphoma C57Bl/6 (H-2b)[ 12]
Myc/BCRHEL/HEL Burkitt-like lymphoma C57Bl/6 (H-2b)[ 13]
Eμ-myc From follicular to DLBCL (time dependant) C57Bl/6 × sv129 [14]
RzCD19Cre NHL, hepatitis C induced 129/Sv (H-2bc); BALB/c (H-2d); C57Bl/6 (H-2b)[ 15]
UVB induced Mature B-cell lymphoma C57Bl/6 p53+/− (H-2b)[ 16]
cell lymphoma, developed by Ford and colleagues [12]b y
generationofdouble-transgenic mice forthe IL-14a and myc
genes (Table 3). A more recent model with the full genome
of the hepatitis C virus introduced into CD19-expressing
cells spontaneously develops human diﬀuse large B-cell
lymphoma [15]. A nontransgenic strategy also led to the
development of a model of mucosa-associated lymphoid tis-
sue lymphoma, shown to recapitulate most human disease
characteristics [48].
The major advantage of the after mentioned models
is that they develop through multiple spontaneous genetic
events that will help us to discover novel mechanisms of tu-
morigenesis. At the same time, they are also associated with
some experimental limitations. First, time to onset of disease
varies enormously within and between models (from day 32
to day 600 for some models), precluding the assessment of
new therapies in these conditions. Moreover, as described
previously, tumor incidence is high but disparate, up to
100% in some cases, but not higher than 25% in others.
Furthermore,inagivenmodel system, thesetumorscanvary
greatly in tumor location and phenotype, which makes it
diﬃcult to compare diﬀerent animals in the same experi-
ment. While it is clear that spontaneous B-cell lymphoma
models provide unique insight into tumor development,
we must nonetheless bear in mind that the in vivo tumor
generation process is quite complex. These models, together
with the adoptive tumor transfer models, will be critical to
our understanding of lymphomagenesis.
3.Models to StudytheLymphoma
Microenvironment
The tumor microenvironment is an essential and compli-
cating aspect of a tumor that must be better understood if
more targeted treatments are to be developed [49]. Studying
all the features of a malignancy requires working on syn-
geneic models. Moreover, reproducible models with well-
characterized tumor development are important for the
analysis ofimmune response, which remains impossible with
spontaneous models. Two main questions must be addressed
in developing such models: the tumor cells to be injected
and the site of tumor injection, that is, nodal or extranodal,
in the peripheral or central nervous system. The tumor
cells are of human origin and therefore implanted into
immunodeﬁcient mice, or, more often, they are syngeneic to
their host, so the tumor-induced immunity can be studied
(Table 2). Lymphomas can invade many diﬀerent organs in
humans, especially secondary lymphoid organs and the
central nervous system. Tumor cells may be injected into
theseorgansinthemouseordirectlyintotheblood;thelatter
allows spontaneous tumor colonization to diﬀerent loca-
tions. The advantages of targeting a speciﬁc tissue include
the possibility of comparing tumorgrowth between diﬀerent
microenvironments and determining the relative roles in
tumor development of the tissue characteristics and the
intrinsic tumor cell characteristics [50].
To study the microenvironment of B-cell lymphomas in
diﬀerent tissues, we implanted a tumor cell line derived from
the well-known A20tumorinto diﬀerenttissue locations, in-
cluding the spleen, brain, and eyes, in syngeneic mice [45,
50]. As Figure 2 illustrates, T cells inﬁltrated the tumor at
each location, even immune-privileged tissues, and repre-
sented up to 15% of all live cells in these sites. Moreover,
antigen-presenting cells also inﬁltrated intotheA20.IIA-GFP
tumor,particularly inthebrainwhere CD11c+ dendriticcells
and CD11b+CD11c− macrophages accounted for a higher
proportion of cells than in the tumor-bearing eye or spleen.
Innate immune cells were also found in the tumor microen-
vironment, especially in the brain and spleen (Figure 2). The
absenceofspontaneoustumorrejectionintheseexperiments4 Advances in Hematology
Table 2: Most common B lymphoma cell lines. B-NHL: non-Hodgkin B-cell lymphoma; DLBCL: diﬀuse large B-cell lymphoma; N/A: not
attributable.
Name Orgin Strain (haplotype) Reference
L1210 Ascitic ﬂuid of 8 months mouse, lymphocytic leukemia
cells DBA/2 (H-2d)[ 19]
Raji Burkitt lymphoma from an 11-year-old child (maxilla) N/A [20]
Jijoye Lymphoblastic cell line derived from a 7-year old boy with
Burkitt lymphoma EBV+ N/A [21]
Daudi 16-year-old black male with Burkitt lymphoma, orbital
tumor N/A [22]
Ramos Burkitt lymphoma N/A [23]
BJAB Burkitt lymphoma N/A [24]
SU-DHL-4 DLBCL patient (peritoneal eﬀusion of woman with
B-NHL) N/A [25]
38C13 Carcinogen induced C3H/HeN (H-2k)[ 26]
BCL1 Spontaneous BALB/c (H-2d)[ 27]
A20 Spontaneous reticulum cell sarcoma of an old mouse BALB/c (H-2d)[ 28]
CA46 Ascite ﬂuid of a patient with Burkitt lymphoma N/A [29]
MC116 Undiﬀerenciated B cell lymphoma N/A [29]
4TOO Plasmacytoma originating from MPC-11 cells BALB/c (H-2d)[ 30]
B6 spontaneous model Spontaneous C57Bl/6 (H-2b)[ 31]
L3055 Burkitt’s lymphoma of germinal center origin N/A [32]
SC-1 Burkitt lymphoma N/A [33]
CH44 Follicular center cell lymphoma derived from
B10.H-2a/H-4bp/Wts, large cell type B10.H-2aH-4bp/Wts (H-2a-4b)[ 34]
DoHH-2 Pleural ﬂuid of 60-year old man with centroblastic
non-Hodgkin lymphoma N/A [35]
S11 From Gammaherpesvirus-68-infected mice BALB/c (H-2d)[ 36]
LY-ar / LY-as Derived from the spontaneous LY-TH tumor C3Hf/kam [37]
Granta 519 Peripheral blood at relapse of high grade B-NHL N/A [38]
Pi-BCL1 Prolymphocytic, foetal liver derived BALB/c (H-2d)[ 39]
38C13 Her2/neu Carcinogen induced C3H/HeN (H-2k)[ 40]
Myc5-M5 Derived from a tumor induced in p53 null mice infected
with myc encoding retrovirus C57Bl/6 (H-2b)[ 18]
Mouse lymphosarcoma cell line Nitrosomethylurea induced CBA (H-2k)[ 41]
FL5.12 transfected by Bcl2 IL-3-dependant BALB/c pro-B cell line BALB/c (H-2d)[ 42]
38C13 CD20+ Carcinogen induced C3H/HeN (H-2k)[ 43]
Z138 Mantle cell lymphoma with blastoid transformation N/A [44]
A20.IIA-GFP / IIA1.6-GFP Reticulum cell sarcoma BALB/c (H-2d)[ 45]
HKBML Brain lymphoma N/A [46]
indicates an immunosuppressive environment. Strikingly,
nonetheless, even immune-privileged sites such as the eye
or the brain were able to induce an immune response, with
cellular and molecular environments similar to those of
peripheral tissue sites. These ﬁndings suggest that the pri-
mary regulator of the tumor microenvironment is the tumor
itself rather than the local tissue structure.
Even so, we note some features speciﬁc to CNS tumors,
in particular the delay in the inﬁltration of T cells, especially
CD8+ T cells, into the eye and the brain. Moreover, we ob-
served among these inﬁltrated T cells a large proportion of
CD4+CD25+Foxp3+ regulatory T cells, accounting for up to
40% of all CD4+ T lymphocytes, compared with no more
than 20% in the spleen [50]. In related ﬁndings, Elpek and
colleagues [74], using the parental A20 cell line implanted
subcutaneously, highlighted the importance of regulatory T
cells in the early phase of tumor growth. Curti’s group [60]
used the same cell line in an intrasplenic tumor model to
study the accumulation of regulatory T cells in the spleen
and showed that the IDO enzyme is critical for the local
conversion of conventional T cells into regulatory ones.
Seraﬁni’s team [75] showed that a robust expansion of spe-
ciﬁc regulatory T cells follows intravenous injection of A20
cells and demonstrated that a populationof myeloid-derived
suppressive cells is responsible for this expansion. Others
have also suggested that myeloid-derived cells can contributeAdvances in Hematology 5
Table 3: Induced models of B-cell lymphoma. (m): murine origin; (h): human origin; (i): syngeneic models; (ii): syngeneic models with
murine tumor cells engineered to express human antigens; (iii): xenogenic models; (iv): humanized models; CLL: chronic lymphocytic
leukemia; DLBCL: diﬀuse large B-cell lymphoma; MALT: mucosa associated lymphatic tissue; n.d.: not determined; PCL: primary cerebral
lymphoma; PCNSL: primary central nervous system lymphoma; PIOL: primary intraocular lymphoma; SCID: severe combined immune
deﬁciency.
Injection site Name Lymphoma model
Recipient mice Major
reference Strain (haplotype) MHC compatibility Immune status
Intravenous B6 spontaneous
model (m)
High-grade B
lymphoma C57Bl/6 (H-2b) Syngeneic (i) Immunocompetent [51]
Pi-BCL1 (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [52]
38C13 (m) Non-Hodgkin
lymphoma C3H/HeN (H-2k) Syngeneic (i) Immunocompetent [53]
FL5.12 transfected by
Bcl2 (m)
Non-Hodgkin
lymphoma BALB/c (H-2d) Syngeneic (i) Immunocompetent [42]
A20 (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [54]
4TOO (m) n.d. BALB/c (H-2d) Syngeneic (i) Immunocompetent [55]
BCL1 (m) CLL BALB/c (H-2d) Syngeneic (i) Immunocompetent [56]
38C13 Her2/neu (m) Non-Hodgkin
lymphoma C3H/HeN (H-2k) Syngeneic (ii) Immunocompetent [40]
Z138 (h) Human mantle cell
lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [57]
BJAB (h) Burkitt lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [58]
SU-DHL-4 (h) DLBCL SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [59]
Intrasplenic A20 (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [60]
A20.IIA-GFP (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [50]
Intraperitoneal CH44 (m) Non-Hodgkin
lymphoma B10.H-2aH-4bp/Wts Syngeneic (i) Immunocompetent [34]
BCL1 (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [53]
38C13 (m) Non-Hodgkin
lymphoma C3H/HeN (H-2k) Syngeneic (i) Immunocompetent [53]
Tonsillar lymphocytes
and EBV infection (h)
Viro-induced
lymphoma
BNXhum
(humanized) Allogenic (iv) Immunocompetent [61]
Subcutaneous LY-ar or LY-as (m) n.d. C3Hf/kam (H-2k) Syngeneic (i) Immunocompetent [37]
S11 (m) Burkitt lymphoma BALB/c nude (H-2d) Syngeneic (i) T-cell deﬁciency [62]
LMycSN-p53null (m) Non-Hodgkin
lymphoma C57Bl/6 (H-2b) Syngeneic (i) Immunocompetent [18]
A20 (m) DLBCL BALB/c (H-2d) Syngeneic (i) Immunocompetent [63]
38C13 Her2/neu (m) Non-Hodgkin
lymphoma C3H/HeN (H-2k) Syngeneic (ii) Immunocompetent [40]
Myc5-M5 (m) n.d. SCID mice (H-2d) Allogenic Immunodeﬁcient [17]
Splenic Hodgkin
lymphoma cells (h) Hodgkin disease Nude mice (H-2b) Xenogenic (iii) T-cell deﬁciency [64]
Human hodgkin cell
line (h) Hodgkin disease SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [47]
Ramos (h) Burkitt lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [58]
BJAB (h) Burkitt lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [58]
SC-1 (h) Follicular lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [58]
DoHH-2 (h) Follicular lymphoma SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [58]
SuDHL-4 (h) DLBCL C.B-17 SCID mice
(H-2d) Xenogenic (iii) Immunodeﬁcient [65]
Granta 519 (h) Mantle cell
lymphoma
C.B-17 SCID mice
(H-2d) Xenogenic (iii) Immunodeﬁcient [65]
HKBML (h) Brain DLBCL C.B-17 SCID mice
(H-2d) Xenogenic (iii) Immunodeﬁcient [46]6 Advances in Hematology
Table 3: Continued.
Injection site Name Lymphoma model
Recipient mice Major
reference Strain (haplotype) MHC compatibility Immune status
Daudi (h) Burkitt lymphoma SCID/beige mice
(H-2d) Xenogenic (iv) Partially rebuilt [66]
Jijoye (h) Burkitt lymphoma SCID/beige mice
(H-2d) Xenogenic (iv) Partially rebuilt [66]
Intramuscular MSV-MuLV-M
induced
Waldenstrom’s
macroglobulinemia C57Bl/6 (H-2b) Syngeneic Immunocompetent [67]
Mouse
lymphosarcoma cell
line (m)
Non-Hodgkin
lymphosarcoma CBA (H-2k) Syngeneic (i) Immunocompetent [41]
Stomach Helicobacter felis MALT lymphoma BALB/c (H-2d) Syngeneic (i) Immunocompetent [48]
Intracerebral A20.IIA-GFP (m) PCL (PCNSL) BALB/c (H-2d) Syngeneic (i) Immunocompetent [50]
38C13 CD20+ (m) PCL (PCNSL) C3H/HeN (H-2k) Syngeneic (ii) Immunocompetent [68]
Raji (h) PCL (PCNSL) Nude mice (H-2b) Xenogenic (iii) T-cell deﬁciency [69]
Patient’s cells (h) PCL (PCNSL) Nude mice (H-2b) Xenogenic (iii) T-cell deﬁciency [70]
MC116 (h) PCL (PCNSL) Nude rats (RT1u) Xenogenic (iii) Immunodeﬁcient [71]
Cisterna
magna L1210 (m) Leptomeningeal
metastases DBA/2 (H-2d) Syngeneic (i) Immunocompetent [72]
Intraocular A20.IIA-GFP (m) PIOL BALB/c (H-2d) Syngeneic (i) Immunocompetent [45]
38C13 CD20+ (m) PIOL C3H/HeN (H-2k) Syngeneic (ii) Immunocompetent [68]
CA46 (h) PIOL SCID mice (H-2d) Xenogenic (iii) Immunodeﬁcient [73]
to the tumor immune response, as when M2 macrophages
inﬁltrate the B-cell lymphoma growing in the brain after
implantation of human Raji cells into nude mice [76].
All these results show that B-cell lymphomas induce im-
munosuppressive cells, although how these cells contribute
to tumor growth remains unknown. It is assumed that
suppressive myeloid cells can inﬂuence the molecular milieu
of the tumor. We and others have shown the production
of various anti-inﬂammatory mediators, depending on the
experimental setting, including IL-10 [74], IL-4 [76], and
soluble receptor for IL-2 [15]. Additionally, as Figure 2
shows,wefoundthatTcellsfromtumor-bearingmicedonot
produce the proinﬂammatory cytokines IFNγ or GM-CSF
without stimulation, except in the spleen where resident T
cells might be responsible for this secretion. After polyclonal
stimulation we observed an unbalanced Th1/Th17 proﬁle,
with high levels of IFNγ, GM-CSF, and IL-17 and low levels
of IL-2, IL-4, and IL-10 [45, 50].
In summary, it is clear that tumor cells closely regulate
the microenvironment of B-cell lymphomas. It is advanta-
geous for the tumor to generate a suppressive environment
for optimal tumor growth. Understanding the balance be-
tween pro- and anti-inﬂammatory mediators that can con-
tribute to or control tumor growth is essential for designing
novel tumor therapies.
4.Modelsto Analyze the Efﬁcacyof
New Therapies
4.1. Assessment of Treatment Eﬃcacy. In recent years, tumor
therapies have achieved substantial but still incomplete suc-
cess. It is generally accepted that well-characterized human
tumor cell lines and in vivo animal models are required to
develop novel antitumor treatments. Basically, four types of
models have been developed (Table 3): (i) syngeneic murine
models, (ii) syngeneic models with murine tumor cells en-
gineered to express human antigens, (iii) human cells im-
planted into immunodeﬁcient mice, and (iv) humanized
mice, that is immunodeﬁcient mice reconstituted with hu-
man immune system andthenimplanted withhuman tumor
cells.
The standard treatment for aggressive B-cell malignan-
cies is the combination of four chemotherapy agents (i.e.,
cyclophosphamide, doxorubicin, vincristine, and prednisol-
one) with rituximab, also called R-CHOP therapy [77].
Because B-lymphoma cells express the CD20 antigen, they
are a suitable target for anti-CD20 monoclonal antibodies
(mAb) such as rituximab. The use of this chimeric mAb has
enhanced the survival of patients with diﬀerent B-cell malig-
nancies, after various studies conﬁrmed its therapeutic
potential. Most of those studies used murine models of hu-
man tumor cell lines implanted into immunodeﬁcient mice.
For example, the eﬃcacy of rituximab against disseminated
BurkittlymphomaDaudicellsandagainstDLBCLSU-DHL4
cells was assessed in SCID mice, and the therapeutic advan-
tagesvariedwiththecellline[59].Hernandez-Ilizaliturriand
colleagues [78] also used SCID mice, with the Raji cell line,
and obtained better results: rituximab treatment enabled
60% of the animals to reject their tumors. This great poten-
tial has led many laboratories to seek to improve this eﬃcacy
by designing new engineered antibodies, such as EMAB-6
[79] or the humanized GA101 used against the human SU-
DHL4 tumor implanted into SCID/beige mice [80]. Cou-
pling rituximab with other therapies has also been evaluatedAdvances in Hematology 7
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Figure 2: Comparison of the cellular and molecular immune environment of a B cell murine lymphoma implanted in the spleen, in the
brainorintheeye. (a)A20.IIA-GFP cellswere implantedinimmunocompetentsyngeneicmice inthespleen (intraspleniclymphomamodel:
ISL),in the brain (primary intracerebral lymphomamodel: PCL), or in the eye (primary intraocular lymphomamodel: PIOL).21 days after
injection, tumor-bearing organs were analyzed by ﬂow cytometry for the presence of GFP+ tumor cells, CD3+ T lymphocytes, NKp46+ NK
cells, Gr1+ neutrophils,CD11c+ dendritic cells, and CD11b+CD11c− macrophages.Results are represented as the proportion of the diﬀerent
populations among total living cells (n = 10). (b) 21 days after lymphoma (gray boxes) or PBS (white boxes) injection, cells were isolated
from appropriate tissues and stimulated for 36 h with anti-CD3/CD28-coated Dynal beads. Secretion of IL-2, IFNγ, GM-CSF, IL-4, IL-10,
and IL-17 in the culture supernatant was evaluated by cytokine bead arrays (BD Biosciences) (n = 10). Animal studies were conformed to
European Union guidelines and were approved by the Charles Darwin Ethics Committee in Animal Experiment, Paris, France.Advances in Hematology 9
in these murine models of human tumors, as, for example,
withR-CHOPtherapy[81],ortheTLR9agonistCpGagainst
Daudi cells [82]. Advances in understanding the biology of
tumorcells and the tumormicroenvironment have led to the
design of new therapies, combined or not with preexisting
ones (for review, see [83]). All of these strategies have been
evaluated by implanting human cell lines into immunodeﬁ-
cient mice. They include the application of immunomodu-
latory drugs ([84]: subcutaneous Raji cells into SCID mice),
inhibition of antiapoptotic signals ([65]: diﬀerent cell lines
into SCID or SCID/beige mice), or inhibition of speciﬁc
metabolicorsignalingpathways([69]:intracerebralRajicells
into nude mice; [46]: subcutaneous HKBML cells into SCID
mice).Newstrategies arealsoevaluatedinthisway,including
the use of immunoconjugates ([73]: intraocular CA46 cells
into SCIDmice; [85]: intravenousRaji cellsinto SCIDmice),
or reoviruses, which target cells expressing high levels of the
ras oncogene ([86]: subcutaneous Daudi and Raji cells into
SCID/nod mice).
The major disadvantage of the experimental models
described in this subsection is that they involve immunod-
eﬁcient hosts that lack the adaptive immunity present in
tumor microenvironment in humans, that do not reﬂect the
complexity of human diseases.
4.2. Assessment of Immune System Involvement in Tumor Re-
jection. The role of the immune system is essential in tumor
rejection. Syngeneic models, besides their utility in analysis
of the tumor microenvironment, are particularly helpful
for studying how speciﬁc treatments modulate the immune
system or particular components of it. One of the indicators
studied most frequently after treatment is the quantity of T
lymphocytes, especially CD8+ T cells, inﬁltrating the tumor
[87]. In an A20 B-cell lymphoma model implanted subcu-
taneously, treatment by survivin oranidiotype-binding pep-
tide,iscorrelated with increased CD8+ T-cell inﬁltration [63,
88]. Some therapies are clearly designed to boost immune
response. For example, in the 4TOO intravenous model,
administration of a vaccine composed of a fusion between
dendritic cells and tumor cells increases T-lymphocyte pro-
liferation and promotes the secretion of IL-2, IL-6, and IFNγ
(model listed in Table 3). In this model, signiﬁcant amounts
ofIL-17 are found, which suggeststhat Th17-expressing cells
contribute to tumor rejection [55]. Houot and Levy [87],
in a two-site subcutaneous A20 model, tried to design an
antitumor therapy based on the intratumoral inoculation of
CpGandtwoT-cell-modulatingmAbs.Theyobtainedstrong
response rates and were able to demonstrate the involvement
ofCD4+ T cellsin controlling the primary tumorsite and the
role of CD8+ T cells in controlling distant tumors.
Another signiﬁcant advantage of murine models is the
abundance of diﬀerent mutant mice, deﬁcient for well-
characterized molecules or cell populations. For example, a
subcutaneous Raji lymphoma model implanted into Fcγ-
receptor-deﬁcient mice demonstrated the importance of Fc
receptors in the therapeutic eﬃcacy of cytotoxic antibodies
and the abolition of the anti-CD20 rituximab antitumor
eﬀect [89]. Additionally, Flynn and Stockinger [90] studied
the role of speciﬁc CD4+ populations in the subcutaneous
LK35 tumor model with Rag−/−γc−/− mice that lack all
lymphocytes and NK cells. They demonstrated that memory
T cells were capable of controlling tumor growth initially,
withoutthehelpofothercomponentsoftheimmunesystem.
However, immune pressure eventually led to selection of
tumorcellsunabletopresentantigens,which resultedinturn
in paralysis of the T-cell response.
Another potential way to obtain data more relevant to
human tumors is to use murine cell lines expressing speciﬁc
human tumor antigens, which would make it possible to
test monoclonal antibodies against speciﬁc antigens. For
example, the murine 38C13 cell line expressing the human
CD20 antigen has been used to evaluate the therapeutic
potential of rituximab against intravenously injected dis-
seminated tumors [43] and against central nervous system
tumors [68]. The authors showed in the ﬁrst case [43]t h a t
depletion of neutrophils, NK cells, and macrophages did
not inﬂuence antibody eﬃcacy, but complement inhibition
abolished this eﬀect. More recently, others have used the
EL4 thymoma cell line transfected with this same human
CD20 antigen and the luciferase gene to monitor tumor
regression after rituximab therapy [91, 92]. For now, the
best system for studying tumor rejection appears to involve
the reconstitution of immunodeﬁcient mice with human
immune cells to generate humanized mice, followed by the
implantation of human tumor cells into these experimental
animals. Sato and collaborators [93] developed this model
to deﬁne the role of the complement system in the eﬃcacy
of an optimized variant of rituximab. In another example,
human Daudi cells were implanted into SCID mice that
were reconstituted with human peripheral blood leukocytes
to assess the eﬃcacy of a vaccine composed of immature
dendritic cells and antihuman CD40 mAb [94]. This study
demonstrated the rate at which activated CD8+ cytotoxic T
lymphocytes inﬁltrate Burkitt lymphomas and the high level
at which these cells secrete IFNγ after the injection of this
vaccine. More recently, a model was developed to test the
eﬃcacy of an agonistic anti-CD40 antibody against diﬀerent
subcutaneousB-celltumorcelllines,suchasDaudi,Raji,and
Jijoye, implanted into SCID/beige mice. Although this type
of treatment by itself reduced tumor size, it was much more
eﬀective after reconstitution of the mice with human T cells
and dendritic cells [66].
In summary, antitumor immune responses hold great
promise forboosting tumortherapy.Moreappropriatemod-
els are needed to explore the possibility of dendritic cell
vaccinationtherapiesincombinationwithspeciﬁctumorcell
targeting.
5.Conclusion
Recentexperimentalanimalmodelsthatallowustostudythe
induction and developmentof human tumors are important
achievements. Only with a deeper understanding of the mo-
lecularandcellularmechanismsleadingtotumorgenesisand
development of tumor microenvironments can we design
better therapies. Despite the advances with the animal mod-
els described in this paper, several questions remain open.10 Advances in Hematology
Giventhediﬃcultyincomparingmurinetumorsandhuman
malignancies, more relevant models are needed. As this
paper shows, there are many diﬀerent models that seek to
mimic human disease, but no consensus exists for any given
model. Most tumor cells and spontaneous models require
better characterization from histologic, phenotypic, genetic,
and immunologic perspectives. Parallels with human dis-
eases are also complicated by the absence of a clear clas-
siﬁcation of B-cell lymphomas. One interesting future
challenge will be to develop a humanized murine model that
canbeimplantedwith humantumorsandreconstitutedwith
a complete human immune system for each main subclass of
B-cell lymphomas. The remarkable impact that these models
have had on the development of novel tumor therapies
justiﬁes the aggressive pursuit of basic and preclinical in-
vestigations to developmore appropriate animal models and
unravel the fundamental processes governing the interaction
of tumors with host tissues.
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